Monitor for topline Phase 2 data from the PIK-201 trial in endometrial cancer, expected by year-end 2026, which is the next major catalyst. The current cash runway supports operations through this readout.
Price Chart
Executive Summary
Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net loss of $4.9M ($3.91/share) in Q2 2025. The company highlighted that topline Phase 2 data for PIKTOR in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 breast cancer trial. The company has $186.4M in cash and securities, providing runway through key milestones. The filing is a routine quarterly update for a clinical-stage biotech with no revenue and no consensus estimates provided for the current quarter, making it neutral with low impact.
Key Financial Metrics
Key Facts
- Net loss was $16.0M ($2.84/share) for Q2 2026 vs $4.9M ($3.91/share) in Q2 2025.
- Cash, cash equivalents and marketable securities were $186.4M as of June 30, 2026.
- Topline Phase 2 data for PIKTOR in endometrial cancer expected by year-end 2026.
- First patient dosed in Phase 1b/2 trial of PIKTOR in HR+ breast cancer in April 2026.
- Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.
- Stockholders approved conversion of Series B preferred stock into common stock in June 2026.
Financial Impact
Net loss increased to $16.0M from $4.9M YoY; cash position $186.4M provides runway through key clinical milestones.
Risk Factors
- Clinical trial failure or disappointing data for PIKTOR.
- Cash burn rate may require future financing before reaching profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331563 |
| Document: d168633d8k.htm | 0001193125-26-331563 |
| Document: 0001193125-26-331563-index-headers.html | 0001193125-26-331563 |
| Document: 0001193125-26-331563-index.html | 0001193125-26-331563 |
| Document: 0001193125-26-331563.txt | 0001193125-26-331563 |
| 8-K Data (Synthetic) | 0001193125-26-331563 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 3 | $34.24 $31.55 | ▼ −7.86% | ▼ −10.42% | $28.35 (−17.20%) |
Aug 11, 2026 7w ago | 144 | $28.57 $33.00 | ▼ −15.51% | ▼ −15.91% | $28.35 (+0.77%) |
Aug 4, 2026 8w ago | 8-K | $25.50 $30.00 | ▲ +17.65% | ▲ +17.75% | $28.35 (+11.18%) |
Jul 28, 2026 9w ago | 3 | $28.93 $24.59 | ▼ −15.00% | ▼ −20.53% | $28.35 (−2.00%) |
Jul 2, 2026 13w ago | Insider Cluster | $22.92 $32.54 | ▲ +41.97% | ▲ +41.04% | $28.35 (+23.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access